Dr. Lindsay Rosenwald
Dr. Lindsay Rosenwald’s multitudes of achievements in the fields of medical research and biotechnology are based on the foundation of Paramount BioCapital, which he founded in 1991. This company formed the basis for the Paramount Group of Companies, of which he is the Chairman and Founder. Cited as one of the most prolific entrepreneurs in the industry, some of Dr. Rosenwald’s, his companies, and his portfolio companies’ achievements include:
- Paramount Corporate Development. This firm assists Paramount’s many portfolio companies by facilitating and coordinating their drug research and development as well as general corporate development.
- Paramount BioSciences. This global, multi-national drug development and healthcare investment firm focuses on the concepts that drive new drugs and companies that develop those drugs. It provides support and backing for these budding biotech companies.
- Paramount BioCapital. Focusing mainly on the financial and capital side of Paramount’s spectrum, BioCapital determines and locates financial support for Paramount’s portfolio companies and is a registered broker-dealer with the Financial Industry Regulatory Authority, or FINRA. To date, Paramount BioCapital has raised in the range of $950 million for these institutions.
Dr. Rosenwald attended Abington High School in Pennsylvania until 1973, when he moved on to Pennsylvania State University to major in Finance. After graduating Beta Gamma Sigma in 1977, he studied medicine at Temple University’s School of Medicine. He graduated in 1983 and then served an internship at Abington Medical Hospital while establishing his own private practice. In 1986, Dr. Rosenwald shifted his focus to finance and moved to Wall Street, where his unique capacity as both a physician and analyst, a combination of fields that few boasted at that time, formed the foundation for the accomplishments to come.
Paramount BioCapital was founded in 1991 and has since affected the field of medicine and medical research in numerous ways. Arsenic Trioxide was developed by one of his portfolio companies, and it moved from development to FDA approval in record time, faster than any other drug. Johnson & Johnson purchased Cougar Biotechnology, a company founded by Dr. Rosenwald, based solely on abiraterone acetate. Abiraterone acetate was being tested for its use in the treatment of prostate cancer and was not yet in Phase III clinical trials. However, the compound was so promising that Johnson & Johnson purchased Cougar for around $1,000,000,000, even though the drug in question was still in Phase II trials. Dr. Rosenwald also formed the Rosenwald Foundation, a nonprofit that has given millions of dollars in support funds to many medical and scientific research groups. This funding has provided these pioneering researchers with the tools needed to advance high-tech medicine into new paradigms.
With a nearly two-decade-long reputation in many fields of medicine and research, Dr. Lindsay Rosenwald is at the frontier of cutting-edge research and development. His unique combination of disciplines - medicine and finance - allows him to identify and support new research that will broaden the horizons of medicine with an educated and informed eye. Few in the industry can claim to match Dr. Rosenwald’s prolific achievements in a very specialized industry.